At a glance
- Originator Nonindustrial source
- Class Antineoplastics; Pyrimidines; Small molecules
- Mechanism of Action CDC2 protein kinase inhibitors; Cyclin-dependent kinase 2 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 05 Oct 1999 New profile
- 05 Oct 1999 Preclinical development for Cancer in United Kingdom (Unknown route)